Q2037 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ2037
- Long description
- Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Short description
- Fluvirin vacc, 3 yrs & >, im
- Pricing indicator
54Vaccinations- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1GImmunizations/Vaccinations- Added
- January 1, 2011
- Last change
- January 1, 2014 – No change
Frequently asked questions
What is HCPCS code Q2037?
Q2037 is a HCPCS Level II code for influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin).
Does Medicare cover Q2037?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q2004 – Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009 – Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2017 – Injection, teniposide, 50 mg
- Q2026 – Injection, radiesse, 0.1 ml
- Q2028 – Injection, sculptra, 0.5 mg
- Q2034 – Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2038 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039 – Influenza virus vaccine, not otherwise specified
- Q2040 – Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q2041 – Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042 – Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043 – Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2049 – Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2050 – Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.